KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses: 2017-2024

Historic Operating Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $88.3 million.

  • Aquestive Therapeutics' Operating Expenses rose 11.24% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.2 million, marking a year-over-year increase of 23.98%. This contributed to the annual value of $88.3 million for FY2024, which is 34.48% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Operating Expenses of $88.3 million as of FY2024, which was up 34.48% from $65.7 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Operating Expenses registered a high of $89.7 million during FY2022, and its lowest value of $65.7 million during FY2023.
  • Over the past 3 years, Aquestive Therapeutics' median Operating Expenses value was $88.3 million (recorded in 2024), while the average stood at $81.3 million.
  • In the last 5 years, Aquestive Therapeutics' Operating Expenses declined by 26.81% in 2023 and then skyrocketed by 34.48% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Operating Expenses (Yearly) stood at $88.7 million in 2020, then dropped by 3.64% to $85.5 million in 2021, then climbed by 4.95% to $89.7 million in 2022, then decreased by 26.81% to $65.7 million in 2023, then skyrocketed by 34.48% to $88.3 million in 2024.